Long non‑coding RNA NNT‑AS1 contributes to cell proliferation, metastasis and apoptosis in human ovarian cancer

Huang,Yaqing; Shi,Junyu; Xu,Yun

doi:10.3892/ol.2018.8492

Long non‑coding RNA NNT‑AS1 contributes to cell proliferation, metastasis and apoptosis in human ovarian cancer

Authors:
- Yaqing Huang
- Junyu Shi
- Yun Xu
View Affiliations

Affiliations: Department of Gynecology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China
Published online on: April 13, 2018 https://doi.org/10.3892/ol.2018.8492
Pages: 9264-9270

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is a markedly heterogeneous malignancy characterized by various histological subtypes. Molecular biomarkers have been indicated to serve significant functions in the early diagnosis and treatment of early‑stage ovarian cancer. However, the detailed mechanism underlying the tumorigenesis of ovarian cancer remains unclear. The present study aimed to identify a novel long non‑coding RNA in patients with ovarian cancer. Nicotinamide nucleotide transhydrogenase‑antisense 1 (NNT‑AS1) was markedly downregulated in patients with ovarian cancer and in cultured human ovarian cancer cells. Knockdown of NNT‑AS1 in the human ovarian cancer cell lines HO‑8910 and SK‑OV‑3 promoted colony formation and arrested the cell cycle at G0/G1 phase. Furthermore, Transwell demonstrated that the downregulation of NNT‑AS1 increased cell migration and invasion by ~60 and 70%, respectively, in HO‑8910 and SK‑OV‑3 cells. Furthermore, cell apoptosis was inhibited by the transfection of siNNT‑AS1 in the two cell lines, whereas the relative activities of caspase‑3 and caspase‑9 were decreased. These results indicated a protective function of NNT‑AS1 in human ovarian cancer, providing novel insights into the diagnosis and treatment of ovarian cancer in clinical settings.

View Figures

View References

1	Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI
2	Vergote I, Oaknin A, Baurain JF, Ananda S, Wong S, Su X, Wu B, Zhong Z, Warner D and Casado A: A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery. Eur J Cancer. 50:2408–2416. 2014. View Article : Google Scholar : PubMed/NCBI
3	Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS and Casado A: Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. Eur J Cancer. 47 Suppl 3:S88–S92. 2011. View Article : Google Scholar : PubMed/NCBI
4	Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, Tateo S, Franchi M, Jobsen JJ, Coens C, et al: Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 44:808–818. 2008. View Article : Google Scholar : PubMed/NCBI
5	Pinsky PF, Yu K, Kramer BS, Black A, Buys SS, Partridge E, Gohagan J, Berg CD and Prorok PC: Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up. Gynecol Oncol. 143:270–275. 2016. View Article : Google Scholar : PubMed/NCBI
6	Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, et al: Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): A randomised controlled trial. Lancet. 387:945–956. 2016. View Article : Google Scholar : PubMed/NCBI
7	Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, et al: Landscape of transcription in human cells. Nature. 489:101–108. 2012. View Article : Google Scholar : PubMed/NCBI
8	Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, et al: The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression. Genome Res. 22:1775–1789. 2012. View Article : Google Scholar : PubMed/NCBI
9	Melissari MT and Grote P: Roles for long non-coding RNAs in physiology and disease. Pflugers Arch. 468:945–958. 2016. View Article : Google Scholar : PubMed/NCBI
10	Lin CY, Kleinbrink EL, Dachet F, Cai J, Ju D, Goldstone A, Wood EJ, Liu K, Jia H, Goustin AS, et al: Primate-specific oestrogen-responsive long non-coding RNAs regulate proliferation and viability of human breast cancer cells. Open Biol. 6:1502622016. View Article : Google Scholar : PubMed/NCBI
11	Wang X, Sehgal L, Jain N, Khashab T, Mathur R and Samaniego F: LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2. J Transl Med. 14:3462016. View Article : Google Scholar : PubMed/NCBI
12	Wei S and Wang K: Long noncoding RNAs: Pivotal regulators in acute myeloid leukemia. Exp Hematol Oncol. 5:302016. View Article : Google Scholar : PubMed/NCBI
13	Zhuo C, Jiang R, Lin X and Shao M: LncRNA H19 inhibits autophagy by epigenetically silencing of DIRAS3 in diabetic cardiomyopathy. Oncotarget. 8:1429–1437. 2017. View Article : Google Scholar : PubMed/NCBI
14	Wang Q, Yang L, Hu X, Jiang Y, Hu Y, Liu Z, Liu J, Wen T, Ma Y, An G and Feng G: Upregulated NNT-AS1, a long noncoding RNA, contributes to proliferation and migration of colorectal cancer cells in vitro and in vivo. Oncotarget. 8:3441–3453. 2017.PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta CT)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
17	Yeung TL, Leung CS, Li F, Wong SS and Mok SC: Targeting stromal-cancer cell crosstalk networks in ovarian cancer treatment. Biomolecules. 6:32016. View Article : Google Scholar : PubMed/NCBI
18	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
19	Liu T, Zhang X, Gao S, Jing F, Yang Y, Du L, Zheng G, Li P, Li C and Wang C: Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer. Oncotarget. 7:85551–85563. 2016. View Article : Google Scholar : PubMed/NCBI
20	Spencer SL and Sorger PK: Measuring and modeling apoptosis in single cells. Cell. 144:926–939. 2011. View Article : Google Scholar : PubMed/NCBI
21	Du Y, Gong J, Tian X, Yan X, Guo T, Huang M, Zhang B, Hu X, Liu H, Wang Y, et al: Japonicone A inhibits the growth of non-small cell lung cancer cells via mitochondria-mediated pathways. Tumour Biol. 36:7473–7482. 2015. View Article : Google Scholar : PubMed/NCBI